91Ó°ÊÓ

Antiretrovirals to Prevent HIV A study conducted in Uganda and Kenya looked at heterosexual couples in which one of the partners was HIV-positive and the other was not. The person in each couple who was not HIV-positive was randomly assigned to one of three study regimens: tenofovir (TDF), combination tenofovir-emtricitabine (TDF-FTC), or placebo and was followed for up to 36 months. Seventeen of the 1584 people assigned to TDF became positive for HIV, as did 13 of the 1579 assigned to TDFFTC and 52 of the 1584 assigned to the placebo. a. Find the percentage in cach group in the sample that became HIV positive, and compare these percentages. b. Create a two-way table with the treatment labels across the top. c. Test the hypothesis that treatment and HIV status are associated using a significance level of \(0.05\). (Source: J. Baelen et al. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine \(367,399-410\), August.)

Step by step solution

01

Calculate the Percentages

To find the percentage in each group that became HIV positive, the number of individuals who became positive in each group should be divided by the total number of individuals in the respective group and then multiplied by 100.\n\nFor TDF: \(\frac{17}{1584} * 100 = 1.07%\)\nFor TDF-FTC: \(\frac{13}{1579} * 100 = 0.82%\)\nFor Placebo: \(\frac{52}{1584} * 100 = 3.28%.\)

02

Create a Two-Way Table

The two-way table should present the treatment labels across the top and corresponding data beneath each treatment.\n\n| | TDF | TDF-FTC | Placebo |\n|-----------|-----|---------|---------|\n| HIV + | 17 | 13 | 52 |\n| Total |1584 | 1579 | 1584 |

03

Test for Association

A Chi-square test for independence is usually conducted to test for an association between two nominal variables using count data. Use Chi-square test of independence with a significance level of \(0.05\). The hypothesis statements are as follows:\nH0 (null hypothesis) is: Treatment and HIV status are not associated.\nHa (alternative hypothesis): Treatment and HIV status are associated. The chi-square test statistic, p-value and whether to reject or fail to reject the null hypothesis are needed to provide a conclusion.\n\nNOTE: The calculated chi-square test statistic and the p-value will depend on the exact chi-square distribution used and thus can't be calculated without additional information or software.

Unlock Step-by-Step Solutions & Ace Your Exams!

• Full Textbook Solutions

  Get detailed explanations and key concepts

• Unlimited Al creation

  Al flashcards, explanations, exams and more...

• Ads-free access

  To over 500 millions flashcards

• Money-back guarantee

  We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

Chi-square Test

The Chi-square test is a fundamental statistical test used to determine whether there is a significant association between two categorical variables. In this context, we are interested in understanding whether the type of antiretroviral treatment is associated with HIV status.
Here’s how it works:

• The test evaluates the observed frequencies in each category against the frequencies that we would expect under the null hypothesis.
• In this scenario, the null hypothesis (\( H_0 \)) states that there is no association between treatment regimen and HIV status, implying that any differences in infection rates arise due to chance.
• The alternative hypothesis (\( H_a \)) claims that there's an association, suggesting that the treatment regimen does affect HIV status.

Once the data is collected, we calculate the test statistic:

• The higher the chi-square statistic, the more unlikely it is that the observed deviations are due to random chance.
• A significance level, typically set at 0.05, is used to decide whether to reject or fail to reject the null hypothesis.
• If the p-value, derived from the chi-square statistic, is lower than this threshold, we reject the null hypothesis, indicating a significant association.

HIV Research

HIV research is vital in the ongoing effort to prevent and treat HIV/AIDS. This particular study aims to explore the effectiveness of antiretroviral regimens in preventing the transmission of HIV in serodiscordant heterosexual couples (where one partner is HIV-positive and the other isn’t).
The motivation behind such studies includes:

• Reducing the incidence of HIV infections by finding effective preventative measures.
• Enhancing the quality of life for individuals at risk of contracting HIV.
• Informing public health policy and prioritizing the distribution of preventive treatments in resource-limited settings.

In the study, three groups were administered different regimens:

• Tenofovir (TDF)
• Combination of Tenofovir/Emtricitabine (TDF-FTC)
• Placebo (no active drug)

By examining the rates of new HIV infections in these groups, researchers aim to draw conclusions about the effectiveness of these regimens. The outcome not only helps in prevention strategies but also informs further pharmaceutical research and development.

Data Analysis

Data analysis is at the heart of research in studies like this one, involving antiretrovirals for preventing HIV. The steps of analysis include:

• Calculation of infection rates: Determining the percentage of individuals in each group who contracted HIV helps reveal the effectiveness of the treatments. As seen, TDF had an infection rate of 1.07%, TDF-FTC at 0.82%, and placebo at 3.28%.
• Creating tables for clarity: A two-way table helps organize the data, with treatment types and corresponding outcomes laid out clearly, enhancing readability and understanding.
• Statistical testing: Using tools like the Chi-square test, data analysis helps to assess whether the observed differences in outcomes are statistically significant.

The insights drawn from these analyses enable researchers to make informed conclusions about the treatment regimens' efficacy.
This data-driven approach ensures the validity of research findings, helping develop evidence-based interventions and policies in the fight against HIV/AIDS.